Los inicios de la fagoterapia en Chile: los doctores Mercedes Perez Matus y Hugo Vaccaro Kosovich / The beginnings of phage therapy in Chile: the doctors Mercedes Perez Matus and Hugo Vaccaro Kosovich

Mercedes Pérez Matus y Hugo Vaccaro Kosovich fueron destacados médicos y microbiólogos de la cátedra ordinaria de Bacteriología de la Facultad de Medicina de la Universidad de Chile. En 1931, ambos médicos fueron contratados por la Facultad de Medicina para reorganizar la convulsionada Cátedra de Bacteriología luego de la crisis política de 1931. En el mismo período el destacado investigador del instituto Pasteur Eugéne Wollman vino a Chile a dirigir el Instituto Sanitas (1929-1931), incorporando en nuestro país el conocimiento sobre los bacteriófagos y las técnicas para su aislamiento. La prolongada labor docente y de investigación de Vaccaro y Pérez se extendió por casi 40 años (1931-1970). Publicaron numerosos artículos científicos, siendo uno de sus temas preferidos, en los primeros años, el estudio de los bacteriófagos que aprendieron junto a Wollman. En la década de los 40, bajo el liderazgo de los Dres. Vaccaro y Pérez, se inició la fagoterapia en Chile.

Mercedes Perez Matus and Hugo Vaccaro Kosovich were distinguished doctors and microbiologists from the ordinary chair of Bacteriology at the Faculty of Medicine of the University of Chile. In 1931, both doctors were hired by the F aculty of Medicine to reorganize the convulsed Chair of Bacteriology after the political crisis of 1931. In the same period, the prominent Pasteur Institute researcher Eugene Wollman came to Chile to direct the Sanitas Institute (1929-1931), incorporating in our country the knowledge about bacteriophages and the techniques for their isolation. The long teaching and research work of Vaccaro and Pérez spanned almost 40 years (1931-1970). They published numerous scientific articles, being one of their favorite topics, in the early years, the study of bacteriophages that they learned together with Wollman. In the 1940s, under the leadership of Drs. Vaccaro and Pérez, phage therapy began in Chile.

[Phage therapy is back - maybe?] / Cent ans après, le retour de la phagothérapie ? - Chroniques génomiques.

Bacteriophages were advocated as therapeutic agents more than a century ago, but the advent of antibiotics relegated them to a very minor role. Today, multi-drug resistant bacteria are a serious health problem, and phage therapy enjoys renewed interest. Recent publications show that it can be effective, but also highlight the serious logistic problems involved in using this approach.

Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields.

Bacteriophages (phages/viruses) need host bacteria to replicate and propagate. Primarily, a bacteriophage contains a head/capsid to encapsidate the genetic material. Some phages contain tails. Phages encode endolysins to hydrolyze bacterial cell wall. The two main classes of phages are lytic or virulent and lysogenic or temperate. In comparison with antibiotics, to deal with bacterial infections, phage therapy is thought to be more effective. In 1921, the use of phages against bacterial infections was first demonstrated. Later on, in humans, phage therapy was used to treat skin infections caused by Pseudomonas species. Furthermore, phages were successfully employed against infections in animals - calves, lambs, and pigs infected with Escherichia coli. In agriculture, for instance, phages have successfully been used e.g., Apple blossom infection, caused by Erwinia amylovora, was effectively catered with the use of bacteriophages. Bacteriophages were also used to control E. coli, Salmonella, Listeria, and Campylobacter contamination in food. Comparatively, phage display is a recently discovered technology, whereby, bacteriophages play a significant role. This review is an effort to collect almost recent and relevant information regarding applications and complications associated with the use of bacteriophages.

A Wake-Up Call: We Need Phage Therapy Now.

The rise of multidrug-resistant bacteria has resulted in an increased interest in phage therapy, which historically preceded antibiotic treatment against bacterial infections. To date, there have been no reports of serious adverse events caused by phages. They have been successfully used to cure human diseases in Eastern Europe for many decades. More recently, clinical trials and case reports for a variety of indications have shown promising results. However, major hurdles to the introduction of phage therapy in the Western world are the regulatory and legal frameworks. Present regulations may take a decade or longer to be fulfilled. It is of urgent need to speed up the availability of phage therapy.

An Alternative Cure: The Adoption and Survival of Bacteriophage Therapy in the USSR, 1922-1955.

Felix D'Herelle coined the term bacteriophage in 1917 to characterize a hypothetical viral agent responsible for the mysterious phenomenon of rapid bacterial death. While the viral nature of the "phage" was only widely accepted in the 1940s, attempts to use the phenomenon in treating infections started early. After raising hopes in the interwar years, by 1945 phage therapy had been abandoned almost entirely in the West, until the recent revival of interest in response to the crisis of antibiotic resistance. The use of phage therapy, however, persisted within Soviet medicine, especially in Georgia. This article explains the adoption and survival of phage therapy in the USSR. By focusing on the Tbilisi Institute of Microbiology, Epidemiology and Bacteriophage (now the Eliava Institute), I argue that bacteriophage research appealed to Soviet scientists because it offered an ecological model for understanding bacterial infection. In the 1930s, phage therapy grew firmly imbedded within the infrastructure of Soviet microbiological institutes. During the Second World War, bacteriophage preparations gained practical recognition from physicians and military authorities. At the dawn of the Cold War, the growing scientific isolation of Soviet science protected phage therapy from the contemporary western critiques, and the ecological program of research into bacteriophages continued in Georgia.

Bacteriophage research - What we have learnt and what still needs to be addressed.

Research on bacteriophages has significantly enhanced our understanding of molecular biology, the genomes of prokaryotic cells, and viral ecology. Phages and lysins offer a viable alternative to the declining utility of antibiotics in this post-antibiotic era. They also provide ideal teaching tools for genomics and bioinformatics. This article touches on the first 100 years of phage research with the author commenting on what he thinks are the highlights, and what needs to be addressed.

Phages Make for Jolly Good Stories.

Phage therapy has an intriguing history. It was widely used from the 1920s until the 1940s. After this period, it was nearly completely forgotten in the Western world, while it continued to be used in the Soviet part of the globe. The study of the history of phage therapy provides valuable input into the present development of the field. Science journalists uncovered much of this history and played an important role in the communication of phage therapy after the fall of the Soviet Union, when it came to the attention of Western researchers and doctors. This interest was fueled by the antibiotic resistance crisis. At this time, communication about phage therapy had a wide potential audience, that encompassed medical experts and researchers, as well as the public, because knowledge about this forgotten therapy was very limited. In such a situation, good communication had and still has the potential to catalyze important discussions among different groups; whereas, bad communication could have considerably hindered and still can hinder the possible renaissance of phage therapy.

The history and promising future of phage therapy in the military service.

The continuous evolvement of bacterial resistance to most, if not all, available antibiotics is a worldwide problem. These strains, frequently isolated from military-associated environments, have created an urgent need to develop supplementary anti-infective modalities. One of the leading directions is phage therapy, which includes the administration of bacteriophages, viruses that specifically target bacteria, as biotherapies. Although neglected in the West until recent years, bacteriophages have been widely studied and clinically administered in the former Soviet Union and Eastern Europe for over a century, where they were found to be incredibly efficient at battling numerous infectious diseases.In this review, we discuss the high potential of phage therapy as a solution for resistant bacterial infectious diseases relating to military medicine. By describing the historical development and knowledge acquired on phage therapy, we define the advantages of bacteriophages for combating resistant bacteria in multiple settings, such as trauma injuries and foodborne illnesses, as a preventive tool and therapy against biological warfare agents, and more. We also present the most recent successful clinical applications of bacteriophages in military settings worldwide.We believe that augmenting military medicine by integrating phage therapy is an important and required step in preparedness for the rapidly approaching post-antibiotic era.

Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.

Bacteriophage (from 'bacteria' and Greek φαγεῖν phagein "to devour" or bacterial eaters) are bacterial viruses that infect and kill bacteria. Bacteriophages (shortly "phages") are among the most common and diverse entities in the biosphere. The estimated number of phages on earth is about 1032. Bacteriophages are often isolated from environmental sources, such as water samples, etc. Felix d'Herelle, one of the discoverers of bacteriophages, was the one who suggested them for therapy of human and animal bacterial infections. This idea was very popular in the world until the advent of antibiotics commercial after which production of therapeutic phages ceased in most of the Western countries, but not in the former Soviet Union. The application of antibiotics in the clinical practice, besides the well-known side effects, entails, in addition, the appearance of the forms of bacteria, resistant to newly synthesized preparations. It was concluded that a European and global strategy to address this gap is urgently needed. Now, faced with the alarming growth of a variety of antibiotic resistant bacterial infections, Western researchers and governments are giving phages a serious look. The phages nowadays are seen as a possible therapy against multi-drug-resistant strains of many bacteria. The therapeutic action of bacteriophages significantly differs from antibiotics, which makes them still active against multi-drug-resistant bacteria. Bacteriophages have a number of other advantages in comparison with antibiotics. First of all, they are efficient against multi-drug-resistant bacteria. The aim of this review was to provide an overview of the past and current experiences in the field of phage therapy in the countries where it has been traditionally applied in the clinical practice. Although the style and quality of old Soviet scientific publications dedicated to phage therapy are not challenging the international standards, there is still valuable information which may not be neglected by modern researchers. This information is especially important as it remained unavailable for the Western scientists before because of the language barriers until now. The goal of this article is to encourage further research on this topic, and facilitate rapid decisions on the development of appropriate regulations, which would ultimately permit the use of phages as therapeutic or preventative medicines in daily clinical practice in the Western countries where multiplying drug-resistant bacteria gradually becomes the greatest life threatening problem.